

## Nexstim

### Pilot studies lift off in depression and pain

25 September 2020

- Nexstim has confirmed that two pilot studies, in severe depression and chronic neuropathic pain, using accelerated iTBS protocols with its NBT SmartFocus navigated TMS (transcranial magnetic stimulation) system will be starting at two leading Finnish university hospitals.
- Accelerated iTBS (intermittent theta burst stimulation) is a form of rTMS (repetitive TMS) where stimulation is given several times per day for one week. It is particularly suited for in-patient therapy. In contrast, conventional TMS therapy involves stimulation given once daily over several weeks.
- The depression pilot study is being carried out at Kuopio University Hospital. The accelerated iTBS protocol will be tested in 10 severe depression patients and the results compared with 10 patients treated by conventional TMS. The patient treatments are expected to complete by end-2020, with study results announced soon after completion.
- The pain pilot study will start at Helsinki University Hospital, where the accelerated iTBS protocol will be tested in 5-10 patients with treatment-resistant chronic neuropathic pain and who have not benefitted from prior 10 Hz rTMS treatment targeted to the motor cortex. Patient treatment will begin in Q420, with an expectation that the study will complete in H121. Again, study results will be announced as soon as possible post-completion.
- These pilot studies exploring the potential of new accelerated therapy protocols in severe depression and chronic neuropathic pain could be the first step to entering a new and attractive in-patient TMS market.

**Trinity Delta view:** Embarking on pilot studies using accelerated iTBS treatment protocols is one of Nexstim's strategic goals for 2020 (outlined in detail in our [August 2020 Update](#)). NBT's highly accurate mapping capabilities, and the FDA approval of the three-minute Thetaburst protocol in 2019, means it is well-suited to use in intensive treatment protocols. These pilot studies in chronic pain and severe depression, at leading Finnish medical centres, will build the currently limited clinical evidence base for an intensive TMS approach in difficult-to-treat patient groups. NBT is already CE marked for both chronic pain and depression, and FDA approved in depression (but not yet FDA approved for pain). Should these pilot studies generate evidence of improved patient outcomes, this should increase the NBT market opportunity extending it into the hospital in-patient setting and also provide compelling differentiation over competing TMS systems. We currently value Nexstim at €32.2m, equivalent to €0.07 per share.

Price	€0.04
Market Cap	€15.4m
Primary exchange	Helsinki
Sector	Healthcare
Company Codes	NXTMH/NXTMS
Corporate client	Yes

#### Company description:

Nexstim is a targeted neuro-modulation company that has developed a proprietary navigated rTMS platform for use in diagnostics (NBS) and therapeutics (NBT). NBS is used in planning brain surgery while NBT is focused on depression and chronic pain. FDA approval for depression was given in 2017, and the focus is on its commercial roll out in the US, Europe and Asia.

#### Analysts

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)

+44 (0) 20 3637 5043

**Franc Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)

+44 (0) 20 3637 5041

Lala Gregorek

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)

+44 (0) 20 3637 5043

Franco Gregori

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)

+44 (0) 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2020 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)